The first hours after your ChondroFiller injection

Leaving the clinic the same day is the norm for ChondroFiller — the appointment is an outpatient, ultrasound-guided injection, with no theatre admission, no incision, and no general anaesthetic required. The whole visit typically takes under an hour from arrival to departure.

Once the injectable collagen scaffold is placed, it gels within 3–5 minutes, bonding directly to the cartilage defect site. The joint is kept still briefly during this window to allow the scaffold to set securely; after that, normal walking to the car or public transport is generally fine.

For most people, the rest of injection day is straightforward: mild local discomfort or a sense of fullness in the joint is possible, but full bed rest is not required. Sedentary and desk-based work can typically resume the following day. The two weeks after the injection do carry specific activity guidance — high-impact loading is restricted during this period — but this is activity modification, not immobilisation. Day-to-day movement continues; it is sustained impact and heavy loading that are paused while the scaffold stabilises in place. What that two-week window looks like in practice, and how the rehabilitation phases unfold beyond it, is covered in the sections that follow.

How the scaffold triggers cartilage repair over time

Understanding why improvement takes months rather than days comes down to the biology of what the scaffold actually does — and, crucially, what it does not do.

ChondroFiller works through a process called acellular matrix-induced chondrogenesis. The scaffold itself contains no living cells; instead, it acts as a three-dimensional framework that recruits the patient's own progenitor and stem cells from the surrounding synovium and subchondral bone. Within days to weeks of injection, those cells migrate into the scaffold matrix and begin to establish themselves. Over the following weeks and months, they mature into chondrocytes — the specialised cells responsible for producing cartilage — as the scaffold provides the structural support they need to organise into functional tissue.

Clinically meaningful new tissue takes roughly five months to establish, though the pace varies with defect size, joint location, and individual biology. The process continues well beyond that point: over the first twelve months, the defect progressively fills as repair tissue matures. By approximately one to two years post-injection, the collagen scaffold has been fully resorbed and replaced by the patient's own mature cartilage tissue.

This sequence — scaffold stabilises, cells migrate, cells mature, new tissue forms, scaffold resorbs — is why ChondroFiller supports the body's own repair processes rather than delivering an instant structural fix. The timeline is inherent to the biology, not a limitation of the treatment approach.

Activity and movement in the first two weeks

Knowing exactly which activities are and are not appropriate in the first fortnight helps with planning work schedules, childcare, and daily travel.

What is generally permitted

• Walking at a comfortable pace
• Desk-based, sedentary, and light office work
• Driving (once any procedural discomfort has settled and you can control the vehicle safely)
• Gentle day-to-day movement — the aim is to prevent stiffness, not to enforce bed rest

What is typically restricted

• Running, jumping, and other high-impact activities
• Contact sports and heavy gym loading
• Sustained weight-bearing exercise through an affected large joint such as the knee or hip

Small joint versus large joint

For injections into smaller joints — hand, wrist, and elbow — the restriction period is often shorter, typically around one to two weeks before comfortable movement resumes. Larger joints such as the knee or hip may carry a slightly longer activity-modification window; your treating specialist will advise the exact duration based on defect location and size.

Importantly, this outpatient injection pathway does not carry the structured multi-phase physiotherapy programme associated with surgical cartilage procedures. The rehabilitation burden is considerably lighter: no mandatory physiotherapy sessions are typically required in the early weeks, and most people manage day-to-day activity without clinical support between appointments.

The written aftercare instructions provided by your treating clinician are the authoritative guide for your specific joint and circumstances — the general principles above should complement, not replace, that individual advice.

When most patients start to feel improvement

For most people, the question that matters most is a simple one: when will things actually feel better?

The typical answer, supported by published clinical experience, is somewhere between six and twelve weeks after the injection. This window broadly aligns with the initial phase of cell migration completing and the early formation of repair tissue beginning to take hold within the scaffold — a biological threshold after which many patients notice a meaningful shift in symptoms.

What that early improvement does not mean is that the process is finished. Benefit typically continues to accumulate well beyond twelve weeks as the repair tissue matures and the scaffold progressively integrates. Patients who notice partial but not complete relief at two or three months should expect further gains rather than a plateau — continued improvement at six to twelve months is a normal part of the timeline, not a sign that something has gone wrong.

The full biological arc — scaffold resorption and replacement by the patient's own mature cartilage — runs to approximately one to two years. Symptomatic recovery and structural maturation are two distinct processes that unfold at different rates; feeling meaningfully better in the early weeks does not depend on waiting for that longer process to complete.

Individual results vary with defect size, joint location, surrounding cartilage quality, and patient biology, so the six-to-twelve-week figure should be read as a typical range rather than a fixed schedule.

What MRI scans show at each stage of recovery

Structural imaging offers an independent check on what the biology and symptom timeline suggest: that repair tissue builds gradually rather than all at once.

When clinicians use MRI to assess progress after scaffold-based cartilage treatment, the standard measurement tool is the MOCART score — a validated system that grades how completely a defect has filled, how well the repair tissue integrates with surrounding native cartilage, and how the surface layer is reconstituting. Scores run from 0 to 100; higher values indicate better structural quality.

Published data from ChondroFiller cohorts shows a clear progression across the first year. At four weeks, mean MOCART scores sit at approximately 65 — reflecting early scaffold integration rather than full defect filling. This is expected at that stage: the scaffold has set and cell migration is under way, but substantial new tissue has not yet formed. By twelve months, mean scores have risen to above 80, indicating more than 80% defect filling and good integration with the surrounding cartilage. Across published cohorts, final scores range from 70 to 87 depending on patient factors such as defect size and location.

Beyond the MOCART figure itself, post-treatment MRI scans in these cohorts have shown reduction in bone marrow oedema, decreased periarticular effusion, and visible widening of the joint space. These structural changes correspond closely to what patients describe in the symptom timeline: reduced pain and morning stiffness, and a sense of the joint settling.

Not every patient will have serial MRI assessments — imaging is used when clinically indicated, not as a routine milestone. Where it is performed, however, the scan findings align with the biological arc described earlier: progressive structural maturation over twelve months rather than an immediate change.

Clinical outcomes and finding the right specialist

Published series provide concrete benchmarks against which patients can calibrate expectations.

In knee patients, IKDC scores have improved by approximately 30 points on average in ChondroFiller cohorts — with one post-market clinical follow-up study recording a mean gain of 32.4 points, sustained and marginally increased at three-year follow-up, reaching a score of 80. To put that figure in context, the accepted minimal clinically important difference for the IKDC — the threshold at which a patient is likely to notice a real-world change — is 16.7 points. A 30-point gain sits well above that threshold. In hip patients, published data show improvements of approximately 33 points on the Harris Hip Score. These figures come from a global evidence base spanning more than 19,000 cases.

Outcomes are not uniform. Defect size, joint location, the quality of the surrounding cartilage, and individual patient biology all influence how the scaffold recruits repair cells and how far function recovers. A patient with a small, contained focal defect in a well-preserved joint will typically have a different prognosis from someone with broader cartilage loss or adjacent joint changes. Establishing which scenario applies requires specialist assessment — imaging review, clinical examination, and a frank discussion of what the evidence supports for that specific joint and presentation.

Search MSK lists specialists across the UK who offer ChondroFiller injection. Filtering by region and specialty is the most practical starting point for identifying a clinician suited to your joint and circumstances.